We greatly appreciate our readers continuing to turn to us for insight on the most critical legal, regulatory and transactional developments, and innovative collaborations transforming health care. Over the past year, McDermott’s Health practice made headlines for our work on
Health & Life Sciences News
Exploring Critical Business and Legal Issues across the Health Care and Life Sciences Industries
Health & Life Sciences News, published by McDermott Will & Emery, focuses on legal and regulatory developments affecting the healthcare and life sciences sectors. The blog covers topics such as healthcare mergers and acquisitions, compliance programs, antitrust considerations, provider collaborations, and the impact of public health emergencies like COVID-19 on healthcare operations and life sciences companies. It also addresses FDA regulatory issues, clinical trial innovations, supply chain challenges, and government assistance programs relevant to healthcare and life sciences businesses. The content includes analysis of transactional, compliance, and policy matters shaping the industry landscape.
Latest from Health & Life Sciences News - Page 5
A Year in Physician Practice Management: For Auld Lang Syne
With equal parts hope and optimism, we look ahead to an eventful New Year. This is particularly true for the physician practice management (PPM) industry: we reflect on the progress of the past while looking forward to the opportunities today’s…
Dealmaking in Life Sciences – Valuations and Partnerships that Work
By Jed Gordon
Technology companies are pouring unprecedented capital, time and energy into the health care and life sciences industry, and are reshaping the deal landscape in the process. The top 10 US tech companies have made $4.7 billion in acquisitions in the…
Pursuing Progress: Collaborative Transformation in Action
It’s the industry disruptors, the unusual partnerships, and the cross-border and cross-sector relationships that are driving Collaborative Transformation in the health care and life sciences organizations. But a Collaborative Transformation takes more than signing paperwork and shaking hands. A successful…
Connecting the Dots: Six Lessons from a Biotech M&A Case Study
By Al Sokol
For biotechs, success involves a several year hike through mazes of complex, cross-border, business, scientific, financial and regulatory issues. During this year’s BIO2018 conference in Boston, McDermott gathered a panel of industry leaders and McDermott practitioners and led a case…
Addressing Conflicts of Interest: It’s a Whole New Ballgame
In a new Governing Health vidcast, McDermott partner Michael Peregrine breaks down why you may need to revamp your conflicts of interest procedures, and how the general counsel and the compliance officer can work together to protect the health…
Best of McDermott’s 2018 Health Care Litigation, Compliance & Investigations Forum
At a time when health care organizations are facing greater financial and reputational costs than ever before, more than 150 health care industry leaders, legal and compliance executives, and investors gathered for McDermott’s Health Care Litigation, Compliance & Investigations Forum…
New Governing Health Podcast: Your Most Pressing Questions About the Economy, Answered
The latest episode of the Governing Health podcast gets back to basics: the board’s responsibility for monitoring the impact of key economic trends and indicators. McDermott partner Michael Peregrine welcomes special guest John Challenger, CEO of executive outplacement firm Challenger,…
Collaborative Transformation: Shaping the Future of Health Care, Together
As the health care and life sciences fields experience ever-increasing levels of disruption, diverse entities across the industry are teaming up to embrace and foster innovation. These new pairings are shaping the future of health care, as organizations come together…
Bills Ban Gag Clauses in Pharmacy Contracts
On October 10, 2018 President Trump signed two bills that ban “gag clauses” in pharmacy contracts. Congress passed the two bills—one for Medicare prescription drug plans (“Know the Lowest Price Act”) that will go into effect in January 2020, and…